Aug 13, 2025 • Motley Fool
SOMEWHAT-BULLISH
Indaptus Posts Narrower Loss in Q2
Indaptus Therapeutics ( NASDAQ:INDP ) , a biotechnology company advancing a novel immunotherapy platform for cancer and infectious diseases, reported its second quarter earnings on August 13, 2025. The most significant headline was its narrower-than-expected net loss, reporting a GAAP loss per ...
Aug 11, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
VANCOUVER, British Columbia, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Jul 28, 2025 • GlobeNewswire
NEUTRAL
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
VANCOUVER, British Columbia, July 28, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Jul 23, 2025 • Benzinga
SOMEWHAT-BULLISH
Quanta Announces Leadership Team Appointment and Highlights Clinical Program Progress
- 25-year industry veteran Vanessa L. Jacoby appointed CBO and CFO, bringing financial and strategic leadership - - Enrollment initiated in dose expansion cohorts in Phase 1 clinical trial of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with KRASG12D-mutant pancreatic, ...
Jul 17, 2025 • GlobeNewswire
NEUTRAL
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
Company to participate in investor conferences in July and August Company to participate in investor conferences in July and August ...